Literature DB >> 22932900

Activation of peroxisome proliferator-activated receptor α (PPARα) suppresses hypoxia-inducible factor-1α (HIF-1α) signaling in cancer cells.

Jundong Zhou1, Shuyu Zhang, Jing Xue, Jori Avery, Jinchang Wu, Stuart E Lind, Wei-Qun Ding.   

Abstract

Activation of peroxisome proliferator-activated receptor α (PPARα) has been demonstrated to inhibit tumor growth and angiogenesis, yet the mechanisms behind these actions remain to be characterized. In this study, we examined the effects of PPARα activation on the hypoxia-inducible factor-1α (HIF-1α) signaling pathway in human breast (MCF-7) and ovarian (A2780) cancer cells under hypoxia. Incubation of cancer cells under 1% oxygen for 16 h significantly induced HIF-1α expression and activity as assayed by Western blotting and reporter gene analysis. Treatment of the cells with PPARα agonists, but not a PPARγ agonist, prior to hypoxia diminished hypoxia-induced HIF-1α expression and activity, and addition of a PPARα antagonist attenuated the suppression of HIF-1α signaling. Activation of PPARα attenuated hypoxia-induced HA-tagged HIF-1α protein expression without affecting the HA-tagged HIF-1α mutant protein level, indicating that PPARα activation promotes HIF-1α degradation in these cells. This was further confirmed using proteasome inhibitors, which reversed PPARα-mediated suppression of HIF-1α expression under hypoxia. Using the co-immunoprecipitation technique, we found that activation of PPARα enhances the binding of HIF-1α to von Hippel-Lindau tumor suppressor (pVHL), a protein known to mediate HIF-1α degradation through the ubiquitin-proteasome pathway. Following PPARα-mediated suppression of HIF-1α signaling, VEGF secretion from the cancer cells was significantly reduced, and tube formation by endothelial cells was dramatically impaired. Taken together, these findings demonstrate for the first time that activation of PPARα suppresses hypoxia-induced HIF-1α signaling in cancer cells, providing novel insight into the anticancer properties of PPARα agonists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22932900      PMCID: PMC3471732          DOI: 10.1074/jbc.M112.367367

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

Review 1.  Peroxisome proliferator-activated receptors: nuclear control of metabolism.

Authors:  B Desvergne; W Wahli
Journal:  Endocr Rev       Date:  1999-10       Impact factor: 19.871

Review 2.  Exploiting tumour hypoxia in cancer treatment.

Authors:  J Martin Brown; William R Wilson
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

3.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

4.  Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer.

Authors:  Yoshihito Yokoyama; Bing Xin; Tatsuhiko Shigeto; Mika Umemoto; Akiko Kasai-Sakamoto; Masayuki Futagami; Shigeki Tsuchida; Fahd Al-Mulla; Hideki Mizunuma
Journal:  Mol Cancer Ther       Date:  2007-04       Impact factor: 6.261

5.  Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.

Authors:  Diana C Birle; David W Hedley
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

6.  PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation.

Authors:  Markus Meissner; Monika Stein; Carmen Urbich; Kerstin Reisinger; Guntram Suske; Bart Staels; Roland Kaufmann; Jens Gille
Journal:  Circ Res       Date:  2003-12-18       Impact factor: 17.367

7.  Inhibition of melanoma metastases by fenofibrate.

Authors:  Maja Grabacka; Wojciech Placha; Przemyslaw M Plonka; Stanislawa Pajak; Krystyna Urbanska; Piotr Laidler; Andrzej Slominski
Journal:  Arch Dermatol Res       Date:  2004-06-15       Impact factor: 3.017

8.  Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer.

Authors:  Tatsuhiko Shigeto; Yoshihito Yokoyama; Bing Xin; Hideki Mizunuma
Journal:  Oncol Rep       Date:  2007-10       Impact factor: 3.906

9.  Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines.

Authors:  Katarzyna Urbanska; Paola Pannizzo; Maja Grabacka; Sidney Croul; Luis Del Valle; Kamel Khalili; Krzysztof Reiss
Journal:  Int J Cancer       Date:  2008-09-01       Impact factor: 7.396

10.  Zinc downregulates HIF-1α and inhibits its activity in tumor cells in vitro and in vivo.

Authors:  Lavinia Nardinocchi; Valentina Pantisano; Rosa Puca; Manuela Porru; Aurora Aiello; Annalisa Grasselli; Carlo Leonetti; Michal Safran; Gideon Rechavi; David Givol; Antonella Farsetti; Gabriella D'Orazi
Journal:  PLoS One       Date:  2010-12-13       Impact factor: 3.240

View more
  34 in total

1.  Anticancer activity of salicin and fenofibrate.

Authors:  Marwa Sabaa; Hassan M ELFayoumi; Shimaa Elshazly; Mahmoud Youns; Waleed Barakat
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-07-21       Impact factor: 3.000

2.  PPARα regulates mobilization and homing of endothelial progenitor cells through the HIF-1α/SDF-1 pathway.

Authors:  Zhongxiao Wang; Elizabeth Moran; Lexi Ding; Rui Cheng; Xun Xu; Jian-xing Ma
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-20       Impact factor: 4.799

3.  Characterization of docosahexaenoic acid (DHA)-induced heme oxygenase-1 (HO-1) expression in human cancer cells: the importance of enhanced BTB and CNC homology 1 (Bach1) degradation.

Authors:  Shuai Wang; Bethany N Hannafon; Roman F Wolf; Jundong Zhou; Jori E Avery; Jinchang Wu; Stuart E Lind; Wei-Qun Ding
Journal:  J Nutr Biochem       Date:  2014-02-04       Impact factor: 6.048

Review 4.  Placenta growth factor mediated gene regulation in sickle cell disease.

Authors:  Vijay K Kalra; Shuxiao Zhang; Punam Malik; Stanley M Tahara
Journal:  Blood Rev       Date:  2017-08-16       Impact factor: 8.250

5.  Peroxisome proliferator-activated receptor-α-mediated transcription of miR-199a2 attenuates endothelin-1 expression via hypoxia-inducible factor-1α.

Authors:  Chen Li; Marthe-Sandrine Eiymo Mwa Mpollo; Caryn S Gonsalves; Stanley M Tahara; Punam Malik; Vijay K Kalra
Journal:  J Biol Chem       Date:  2014-11-11       Impact factor: 5.157

Review 6.  PPAR-α as a key nutritional and environmental sensor for metabolic adaptation.

Authors:  Alejandra V Contreras; Nimbe Torres; Armando R Tovar
Journal:  Adv Nutr       Date:  2013-07-01       Impact factor: 8.701

7.  Fibrate treatment of eEOCs in murine AKI.

Authors:  Daniel Patschan; Katrin Schwarze; Elvira Henze; Susann Patschan; Roman Scheidemann; Gerhard Anton Müller
Journal:  J Nephrol       Date:  2014-01-16       Impact factor: 3.902

8.  Zinc at sub-cytotoxic concentrations induces heme oxygenase-1 expression in human cancer cells.

Authors:  Jing Xue; Shuai Wang; Jinchang Wu; Bethany N Hannafon; Wei-Qun Ding
Journal:  Cell Physiol Biochem       Date:  2013-07-12

9.  Upregulation of Ying Yang 1 (YY1) suppresses esophageal squamous cell carcinoma development through heme oxygenase-1.

Authors:  Judong Luo; Xifa Zhou; Xin Ge; Pengfei Liu; Jianping Cao; Xujing Lu; Yang Ling; Shuyu Zhang
Journal:  Cancer Sci       Date:  2013-09-05       Impact factor: 6.716

10.  Activation of PPARα by clofibrate sensitizes pancreatic cancer cells to radiation through the Wnt/β-catenin pathway.

Authors:  J Xue; W Zhu; J Song; Y Jiao; J Luo; C Yu; J Zhou; J Wu; M Chen; W-Q Ding; J Cao; S Zhang
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.